Gerald McMahon
Directeur Général chez STORM Therapeutics Ltd.
Profil
Gerald McMahon currently works at STORM Therapeutics Ltd., as President, Chief Executive Officer & Director from 2022.
Dr. McMahon also formerly worked at Kolltan Pharmaceuticals, Inc., as President, Chief Executive Officer & Director, Harpoon Therapeutics, Inc., as President, Chief Executive Officer & Director from 2016 to 2021, Poniard Pharmaceuticals, Inc., as Non-Executive Chairman from 2010 to 2012, Oncotelic Therapeutics, Inc., as Independent Director from 2011 to 2016, Trellis Bioscience, Inc., as Director, Celldex Therapeutics, Inc., as Director from 2016 to 2018, MedImmune LLC, as Senior VP-Oncology Innovative Medicines Unit from 2010 to 2012, Sugen, Inc., as President from 1993 to 2004, Pharmacia Corp., as Senior Vice President-Research & Development, Massachusetts Institute of Technology, as Staff Investigator, and Bay City Capital LLC, as Venture Partner.
Dr. McMahon received his undergraduate degree from Rensselaer Polytechnic Institute and doctorate degree in 1980 from Rensselaer Polytechnic Institute.
Postes actifs de Gerald McMahon
| Sociétés | Poste | Début |
|---|---|---|
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Directeur Général | 07/09/2022 |
Anciens postes connus de Gerald McMahon
| Sociétés | Poste | Fin |
|---|---|---|
| HARPOON THERAPEUTICS, INC. | Directeur Général | 26/10/2021 |
| CELLDEX THERAPEUTICS, INC. | Directeur/Membre du Conseil | 05/12/2018 |
| ONCOTELIC THERAPEUTICS, INC. | Directeur/Membre du Conseil | 23/11/2016 |
MedImmune LLC
 MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Corporate Officer/Principal | 01/05/2012 |
| PONIARD PHARMACEUTICALS, INC. | Directeur Général | 05/02/2010 |
Formation de Gerald McMahon
| Rensselaer Polytechnic Institute | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| PONIARD PHARMACEUTICALS, INC. | Health Technology |
| ONCOTELIC THERAPEUTICS, INC. | Health Technology |
| CELLDEX THERAPEUTICS, INC. | Health Services |
| Entreprise privées | 8 |
|---|---|
Sugen, Inc.
 Sugen, Inc. Pharmaceuticals: MajorHealth Technology Sugen, Inc. developed small molecule drugs and related pharmaceutical products. The company was founded on July 1, 1991 and was headquartered in New York, NY. | Health Technology |
Pharmacia Corp.
 Pharmacia Corp. Pharmaceuticals: MajorHealth Technology Pharmacia Corp. developed, manufactured and marketed pharmaceutical products. Prescription pharmaceuticals included general therapeutics, ophthalmology and hospital products including oncology and diversified therapeutics. It also operated in consumer health care, animal health, diagnostics and contract manufacturing and bulk pharmaceutical chemicals. The customers of the group were pharmacies, hospitals, chain warehouses, governments, physicians, wholesalers and other distributors. It was headquartered in Peapack, NJ. | Health Technology |
MedImmune LLC
MedImmune LLC BiotechnologyHealth Technology MedImmune LLC develops medicines for the prevention and treatment of infectious diseases such as cancer and immune system disorders. It offers solutions in the areas of monoclonal antibodies and vaccines for infection, oncology, respiratory disease and inflammation, cardiovascular diseases, and neuroscience. The company was founded by Wayne T. Hockmeyer in 1988 and is headquartered in Gaithersburg, MD. | Health Technology |
Trellis Bioscience, Inc.
 Trellis Bioscience, Inc. BiotechnologyHealth Technology Trellis Bioscience, Inc. is discovers and develops novel human antibody therapeutics. It provides the discovery and development of therapeutic antibodies from human B cells. The firm develops the CellSpot antibody discovery platform, which enables the identification of antibodies directly from human blood. The company was founded by Lawrence Kauvar and Stote Ellsworth in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Kolltan Pharmaceuticals, Inc.
 Kolltan Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Kolltan Pharmaceuticals, Inc. engaged in the development of monoclonal antibody drugs. It focused on the discovery and development of novel antibody-based drugs targeting receptor tyrosine kinases (RTKs) for the treatment of cancer and other diseases. The company was founded by Arthur G. Altschul, Jr. and Joseph P. Schlessinger on November 16, 2007 and was headquartered in New Haven, CT. | Health Technology |
Harpoon Therapeutics, Inc.
 Harpoon Therapeutics, Inc. BiotechnologyHealth Technology Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA. | Health Technology |
Bay City Capital LLC
 Bay City Capital LLC Investment ManagersFinance Bay City Capital LLC (Bay City Capital) is a venture capital firm founded in 1997 by Fred Craves, John Diekman, and Thomas Pritzker. The firm is headquartered in California, United States. | Finance |
STORM Therapeutics Ltd.
STORM Therapeutics Ltd. BiotechnologyHealth Technology Storm Therapeutics Ltd. develops small molecule drugs that target RNA-modifying enzymes. It offers research and development of drug molecules for the treatment of specific cancers. The company was founded by Anthony Kouzarides and Eric Miska on April 21, 2015 and is headquartered in Cambridge, the United Kingdom. | Health Technology |
